Global Male Hypogonadism

Male Hypogonadism Comprehensive Study by Type (Primary hypogonadism(Genetic, congenital), Secondary hypogonadism(Kallman syndrome, pituitary gland tumour)), Application (Kallmann Syndrome, Klinefelters Syndrome, Pituitary Disorders, Others), Therapy (Testosterone Replacement Therapy, Gonadotropin-Releasing Hormones Therapy), Treatment (Radiation, Medication, Surgery), Diagnosed (Hormone tests, Imaging tests), Cause (Congenital, Acquired, Complication of illness), Drug Delivery (Injection, Patch, Gel, Lozenge) Players and Region - Global Market Outlook to 2030

Male Hypogonadism Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Male Hypogonadism
Hypogonadism occurs when your sex glands produce little or no sex hormones, male hypogonadism or testosterone deficiency is a condition in which the body doesn't produce enough of the hormone that plays a vital role in the development and masculine growth during puberty or enough sperm or both. Sex hormones help control secondary sex characteristics such as testicular development in men, and pubic hair growth and sperm production. According to Boston University School of Medicine, approximately 4 to 5 million men in the United States, are affected with hypogonadism and low testosterone levels are commonly seen in older males. More than 60% of men over 65 years of age have free testosterone levels below the normal values of men between 30 to 35 years of age

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Male Hypogonadism market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Astrazeneca Plc. (United Kingdom), Merck & Co. Inc. (United States), Laboratories Genevrier (France), Eli Lilly and Company Ltd. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Bayer AG (Germany), Pfizer Inc.(United States), Allergan Plc. (Ireland), Ferring (Switzerland) and AbbVie Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are IBSA Institut Biochimque (Slovakia) and Endo International Plc. (Ireland).

Segmentation Overview
AMA Research has segmented the market of Global Male Hypogonadism market by Type (Primary hypogonadism(Genetic, congenital) and Secondary hypogonadism(Kallman syndrome, pituitary gland tumour)), Application (Kallmann Syndrome, Klinefelters Syndrome, Pituitary Disorders and Others) and Region.



On the basis of geography, the market of Male Hypogonadism has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapy, the sub-segment i.e. Testosterone Replacement Therapy will boost the Male Hypogonadism market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Radiation will boost the Male Hypogonadism market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosed , the sub-segment i.e. Hormone tests will boost the Male Hypogonadism market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cause, the sub-segment i.e. Congenital will boost the Male Hypogonadism market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Delivery, the sub-segment i.e. Injection will boost the Male Hypogonadism market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
High adoption of hormones therapy with increasing cases of hypogonadism

Market Growth Drivers:
The increasing number of Cases of Male Hypogonadism Worldwide and The Increasing Awareness Among Individuals Regarding Hypogonadism Treatment

Challenges:
High cost associated with the treatment

Restraints:
The adverse effect of the treatment

Opportunities:
Increasing incidence and prevalence of hypogonadism and rise in awareness about hypogonadism

Market Leaders and their expansionary development strategies
In June 2022, Novel testosterone undecanoate capsule launched in US hypogonadism market. The launch of Tlando represents second testosterone replacement therapy product,
In February 2020 Clarus Therapeutics announced the launch of new capsule for the male hypogonadism named JATENZO®. JATENZO is the first and only oral softgel testosterone undecanoate, and the first oral testosterone medicine approved by the U.S. FDA in more than 60 years. JATENZO is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Male Hypogonadism Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Primary hypogonadism(Genetic, congenital)
  • Secondary hypogonadism(Kallman syndrome, pituitary gland tumour)
By Application
  • Kallmann Syndrome
  • Klinefelters Syndrome
  • Pituitary Disorders
  • Others
By Therapy
  • Testosterone Replacement Therapy
  • Gonadotropin-Releasing Hormones Therapy

By Treatment
  • Radiation
  • Medication
  • Surgery

By Diagnosed
  • Hormone tests
  • Imaging tests

By Cause
  • Congenital
  • Acquired
  • Complication of illness

By Drug Delivery
  • Injection
  • Patch
  • Gel
  • Lozenge

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing number of Cases of Male Hypogonadism Worldwide
      • 3.2.2. The Increasing Awareness Among Individuals Regarding Hypogonadism Treatment
    • 3.3. Market Challenges
      • 3.3.1. High cost associated with the treatment
    • 3.4. Market Trends
      • 3.4.1. High adoption of hormones therapy with increasing cases of hypogonadism
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Male Hypogonadism, by Type, Application, Therapy, Treatment, Diagnosed , Cause, Drug Delivery and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Male Hypogonadism (Value)
      • 5.2.1. Global Male Hypogonadism by: Type (Value)
        • 5.2.1.1. Primary hypogonadism(Genetic, congenital)
        • 5.2.1.2. Secondary hypogonadism(Kallman syndrome, pituitary gland tumour)
      • 5.2.2. Global Male Hypogonadism by: Application (Value)
        • 5.2.2.1. Kallmann Syndrome
        • 5.2.2.2. Klinefelters Syndrome
        • 5.2.2.3. Pituitary Disorders
        • 5.2.2.4. Others
      • 5.2.3. Global Male Hypogonadism by: Therapy (Value)
        • 5.2.3.1. Testosterone Replacement Therapy
        • 5.2.3.2. Gonadotropin-Releasing Hormones Therapy
      • 5.2.4. Global Male Hypogonadism by: Treatment (Value)
        • 5.2.4.1. Radiation
        • 5.2.4.2. Medication
        • 5.2.4.3. Surgery
      • 5.2.5. Global Male Hypogonadism by: Cause (Value)
        • 5.2.5.1. Congenital
        • 5.2.5.2. Acquired
        • 5.2.5.3. Complication of illness
      • 5.2.6. Global Male Hypogonadism by: Drug Delivery (Value)
        • 5.2.6.1. Injection
        • 5.2.6.2. Patch
        • 5.2.6.3. Gel
        • 5.2.6.4. Lozenge
      • 5.2.7. Global Male Hypogonadism Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Male Hypogonadism: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astrazeneca Plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Laboratories Genevrier (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company Ltd. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc.(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan Plc. (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ferring (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Male Hypogonadism Sale, by Type, Application, Therapy, Treatment, Diagnosed , Cause, Drug Delivery and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Male Hypogonadism (Value)
      • 7.2.1. Global Male Hypogonadism by: Type (Value)
        • 7.2.1.1. Primary hypogonadism(Genetic, congenital)
        • 7.2.1.2. Secondary hypogonadism(Kallman syndrome, pituitary gland tumour)
      • 7.2.2. Global Male Hypogonadism by: Application (Value)
        • 7.2.2.1. Kallmann Syndrome
        • 7.2.2.2. Klinefelters Syndrome
        • 7.2.2.3. Pituitary Disorders
        • 7.2.2.4. Others
      • 7.2.3. Global Male Hypogonadism by: Therapy (Value)
        • 7.2.3.1. Testosterone Replacement Therapy
        • 7.2.3.2. Gonadotropin-Releasing Hormones Therapy
      • 7.2.4. Global Male Hypogonadism by: Treatment (Value)
        • 7.2.4.1. Radiation
        • 7.2.4.2. Medication
        • 7.2.4.3. Surgery
      • 7.2.5. Global Male Hypogonadism by: Cause (Value)
        • 7.2.5.1. Congenital
        • 7.2.5.2. Acquired
        • 7.2.5.3. Complication of illness
      • 7.2.6. Global Male Hypogonadism by: Drug Delivery (Value)
        • 7.2.6.1. Injection
        • 7.2.6.2. Patch
        • 7.2.6.3. Gel
        • 7.2.6.4. Lozenge
      • 7.2.7. Global Male Hypogonadism Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Male Hypogonadism: by Type(USD Million)
  • Table 2. Male Hypogonadism Primary hypogonadism(Genetic, congenital) , by Region USD Million (2018-2023)
  • Table 3. Male Hypogonadism Secondary hypogonadism(Kallman syndrome, pituitary gland tumour) , by Region USD Million (2018-2023)
  • Table 4. Male Hypogonadism: by Application(USD Million)
  • Table 5. Male Hypogonadism Kallmann Syndrome , by Region USD Million (2018-2023)
  • Table 6. Male Hypogonadism Klinefelters Syndrome , by Region USD Million (2018-2023)
  • Table 7. Male Hypogonadism Pituitary Disorders , by Region USD Million (2018-2023)
  • Table 8. Male Hypogonadism Others , by Region USD Million (2018-2023)
  • Table 9. Male Hypogonadism: by Therapy(USD Million)
  • Table 10. Male Hypogonadism Testosterone Replacement Therapy , by Region USD Million (2018-2023)
  • Table 11. Male Hypogonadism Gonadotropin-Releasing Hormones Therapy , by Region USD Million (2018-2023)
  • Table 12. Male Hypogonadism: by Treatment(USD Million)
  • Table 13. Male Hypogonadism Radiation , by Region USD Million (2018-2023)
  • Table 14. Male Hypogonadism Medication , by Region USD Million (2018-2023)
  • Table 15. Male Hypogonadism Surgery , by Region USD Million (2018-2023)
  • Table 16. Male Hypogonadism: by Cause(USD Million)
  • Table 17. Male Hypogonadism Congenital , by Region USD Million (2018-2023)
  • Table 18. Male Hypogonadism Acquired , by Region USD Million (2018-2023)
  • Table 19. Male Hypogonadism Complication of illness , by Region USD Million (2018-2023)
  • Table 20. Male Hypogonadism: by Drug Delivery(USD Million)
  • Table 21. Male Hypogonadism Injection , by Region USD Million (2018-2023)
  • Table 22. Male Hypogonadism Patch , by Region USD Million (2018-2023)
  • Table 23. Male Hypogonadism Gel , by Region USD Million (2018-2023)
  • Table 24. Male Hypogonadism Lozenge , by Region USD Million (2018-2023)
  • Table 25. South America Male Hypogonadism, by Country USD Million (2018-2023)
  • Table 26. South America Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 27. South America Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 28. South America Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 29. South America Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 30. South America Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 31. South America Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 32. South America Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 33. Brazil Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 34. Brazil Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 35. Brazil Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 36. Brazil Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 37. Brazil Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 38. Brazil Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 39. Brazil Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 40. Argentina Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 41. Argentina Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 42. Argentina Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 43. Argentina Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 44. Argentina Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 45. Argentina Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 46. Argentina Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 47. Rest of South America Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 48. Rest of South America Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 49. Rest of South America Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 50. Rest of South America Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 51. Rest of South America Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 52. Rest of South America Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 53. Rest of South America Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 54. Asia Pacific Male Hypogonadism, by Country USD Million (2018-2023)
  • Table 55. Asia Pacific Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 56. Asia Pacific Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 57. Asia Pacific Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 58. Asia Pacific Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 59. Asia Pacific Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 60. Asia Pacific Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 61. Asia Pacific Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 62. China Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 63. China Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 64. China Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 65. China Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 66. China Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 67. China Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 68. China Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 69. Japan Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 70. Japan Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 71. Japan Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 72. Japan Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 73. Japan Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 74. Japan Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 75. Japan Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 76. India Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 77. India Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 78. India Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 79. India Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 80. India Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 81. India Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 82. India Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 83. South Korea Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 84. South Korea Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 85. South Korea Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 86. South Korea Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 87. South Korea Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 88. South Korea Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 89. South Korea Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 90. Taiwan Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 91. Taiwan Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 92. Taiwan Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 93. Taiwan Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 94. Taiwan Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 95. Taiwan Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 96. Taiwan Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 97. Australia Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 98. Australia Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 99. Australia Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 100. Australia Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 101. Australia Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 102. Australia Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 103. Australia Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 104. Rest of Asia-Pacific Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 105. Rest of Asia-Pacific Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 106. Rest of Asia-Pacific Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 107. Rest of Asia-Pacific Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 108. Rest of Asia-Pacific Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 109. Rest of Asia-Pacific Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 110. Rest of Asia-Pacific Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 111. Europe Male Hypogonadism, by Country USD Million (2018-2023)
  • Table 112. Europe Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 113. Europe Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 114. Europe Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 115. Europe Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 116. Europe Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 117. Europe Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 118. Europe Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 119. Germany Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 120. Germany Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 121. Germany Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 122. Germany Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 123. Germany Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 124. Germany Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 125. Germany Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 126. France Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 127. France Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 128. France Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 129. France Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 130. France Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 131. France Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 132. France Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 133. Italy Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 134. Italy Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 135. Italy Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 136. Italy Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 137. Italy Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 138. Italy Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 139. Italy Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 140. United Kingdom Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 141. United Kingdom Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 142. United Kingdom Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 143. United Kingdom Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 144. United Kingdom Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 145. United Kingdom Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 146. United Kingdom Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 147. Netherlands Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 148. Netherlands Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 149. Netherlands Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 150. Netherlands Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 151. Netherlands Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 152. Netherlands Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 153. Netherlands Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 154. Rest of Europe Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 155. Rest of Europe Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 156. Rest of Europe Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 157. Rest of Europe Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 158. Rest of Europe Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 159. Rest of Europe Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 160. Rest of Europe Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 161. MEA Male Hypogonadism, by Country USD Million (2018-2023)
  • Table 162. MEA Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 163. MEA Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 164. MEA Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 165. MEA Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 166. MEA Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 167. MEA Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 168. MEA Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 169. Middle East Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 170. Middle East Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 171. Middle East Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 172. Middle East Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 173. Middle East Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 174. Middle East Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 175. Middle East Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 176. Africa Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 177. Africa Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 178. Africa Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 179. Africa Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 180. Africa Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 181. Africa Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 182. Africa Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 183. North America Male Hypogonadism, by Country USD Million (2018-2023)
  • Table 184. North America Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 185. North America Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 186. North America Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 187. North America Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 188. North America Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 189. North America Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 190. North America Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 191. United States Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 192. United States Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 193. United States Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 194. United States Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 195. United States Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 196. United States Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 197. United States Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 198. Canada Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 199. Canada Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 200. Canada Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 201. Canada Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 202. Canada Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 203. Canada Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 204. Canada Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 205. Mexico Male Hypogonadism, by Type USD Million (2018-2023)
  • Table 206. Mexico Male Hypogonadism, by Application USD Million (2018-2023)
  • Table 207. Mexico Male Hypogonadism, by Therapy USD Million (2018-2023)
  • Table 208. Mexico Male Hypogonadism, by Treatment USD Million (2018-2023)
  • Table 209. Mexico Male Hypogonadism, by Diagnosed USD Million (2018-2023)
  • Table 210. Mexico Male Hypogonadism, by Cause USD Million (2018-2023)
  • Table 211. Mexico Male Hypogonadism, by Drug Delivery USD Million (2018-2023)
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Company Basic Information, Sales Area and Its Competitors
  • Table 215. Company Basic Information, Sales Area and Its Competitors
  • Table 216. Company Basic Information, Sales Area and Its Competitors
  • Table 217. Company Basic Information, Sales Area and Its Competitors
  • Table 218. Company Basic Information, Sales Area and Its Competitors
  • Table 219. Company Basic Information, Sales Area and Its Competitors
  • Table 220. Company Basic Information, Sales Area and Its Competitors
  • Table 221. Company Basic Information, Sales Area and Its Competitors
  • Table 222. Male Hypogonadism: by Type(USD Million)
  • Table 223. Male Hypogonadism Primary hypogonadism(Genetic, congenital) , by Region USD Million (2025-2030)
  • Table 224. Male Hypogonadism Secondary hypogonadism(Kallman syndrome, pituitary gland tumour) , by Region USD Million (2025-2030)
  • Table 225. Male Hypogonadism: by Application(USD Million)
  • Table 226. Male Hypogonadism Kallmann Syndrome , by Region USD Million (2025-2030)
  • Table 227. Male Hypogonadism Klinefelters Syndrome , by Region USD Million (2025-2030)
  • Table 228. Male Hypogonadism Pituitary Disorders , by Region USD Million (2025-2030)
  • Table 229. Male Hypogonadism Others , by Region USD Million (2025-2030)
  • Table 230. Male Hypogonadism: by Therapy(USD Million)
  • Table 231. Male Hypogonadism Testosterone Replacement Therapy , by Region USD Million (2025-2030)
  • Table 232. Male Hypogonadism Gonadotropin-Releasing Hormones Therapy , by Region USD Million (2025-2030)
  • Table 233. Male Hypogonadism: by Treatment(USD Million)
  • Table 234. Male Hypogonadism Radiation , by Region USD Million (2025-2030)
  • Table 235. Male Hypogonadism Medication , by Region USD Million (2025-2030)
  • Table 236. Male Hypogonadism Surgery , by Region USD Million (2025-2030)
  • Table 237. Male Hypogonadism: by Cause(USD Million)
  • Table 238. Male Hypogonadism Congenital , by Region USD Million (2025-2030)
  • Table 239. Male Hypogonadism Acquired , by Region USD Million (2025-2030)
  • Table 240. Male Hypogonadism Complication of illness , by Region USD Million (2025-2030)
  • Table 241. Male Hypogonadism: by Drug Delivery(USD Million)
  • Table 242. Male Hypogonadism Injection , by Region USD Million (2025-2030)
  • Table 243. Male Hypogonadism Patch , by Region USD Million (2025-2030)
  • Table 244. Male Hypogonadism Gel , by Region USD Million (2025-2030)
  • Table 245. Male Hypogonadism Lozenge , by Region USD Million (2025-2030)
  • Table 246. South America Male Hypogonadism, by Country USD Million (2025-2030)
  • Table 247. South America Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 248. South America Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 249. South America Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 250. South America Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 251. South America Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 252. South America Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 253. South America Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 254. Brazil Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 255. Brazil Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 256. Brazil Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 257. Brazil Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 258. Brazil Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 259. Brazil Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 260. Brazil Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 261. Argentina Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 262. Argentina Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 263. Argentina Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 264. Argentina Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 265. Argentina Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 266. Argentina Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 267. Argentina Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 268. Rest of South America Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 269. Rest of South America Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 270. Rest of South America Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 271. Rest of South America Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 272. Rest of South America Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 273. Rest of South America Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 274. Rest of South America Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 275. Asia Pacific Male Hypogonadism, by Country USD Million (2025-2030)
  • Table 276. Asia Pacific Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 277. Asia Pacific Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 278. Asia Pacific Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 279. Asia Pacific Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 280. Asia Pacific Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 281. Asia Pacific Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 282. Asia Pacific Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 283. China Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 284. China Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 285. China Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 286. China Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 287. China Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 288. China Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 289. China Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 290. Japan Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 291. Japan Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 292. Japan Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 293. Japan Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 294. Japan Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 295. Japan Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 296. Japan Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 297. India Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 298. India Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 299. India Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 300. India Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 301. India Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 302. India Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 303. India Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 304. South Korea Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 305. South Korea Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 306. South Korea Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 307. South Korea Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 308. South Korea Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 309. South Korea Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 310. South Korea Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 311. Taiwan Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 312. Taiwan Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 313. Taiwan Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 314. Taiwan Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 315. Taiwan Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 316. Taiwan Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 317. Taiwan Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 318. Australia Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 319. Australia Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 320. Australia Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 321. Australia Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 322. Australia Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 323. Australia Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 324. Australia Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 325. Rest of Asia-Pacific Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 326. Rest of Asia-Pacific Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 327. Rest of Asia-Pacific Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 328. Rest of Asia-Pacific Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 329. Rest of Asia-Pacific Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 330. Rest of Asia-Pacific Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 331. Rest of Asia-Pacific Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 332. Europe Male Hypogonadism, by Country USD Million (2025-2030)
  • Table 333. Europe Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 334. Europe Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 335. Europe Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 336. Europe Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 337. Europe Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 338. Europe Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 339. Europe Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 340. Germany Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 341. Germany Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 342. Germany Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 343. Germany Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 344. Germany Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 345. Germany Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 346. Germany Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 347. France Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 348. France Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 349. France Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 350. France Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 351. France Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 352. France Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 353. France Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 354. Italy Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 355. Italy Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 356. Italy Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 357. Italy Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 358. Italy Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 359. Italy Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 360. Italy Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 361. United Kingdom Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 362. United Kingdom Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 363. United Kingdom Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 364. United Kingdom Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 365. United Kingdom Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 366. United Kingdom Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 367. United Kingdom Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 368. Netherlands Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 369. Netherlands Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 370. Netherlands Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 371. Netherlands Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 372. Netherlands Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 373. Netherlands Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 374. Netherlands Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 375. Rest of Europe Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 376. Rest of Europe Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 377. Rest of Europe Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 378. Rest of Europe Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 379. Rest of Europe Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 380. Rest of Europe Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 381. Rest of Europe Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 382. MEA Male Hypogonadism, by Country USD Million (2025-2030)
  • Table 383. MEA Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 384. MEA Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 385. MEA Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 386. MEA Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 387. MEA Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 388. MEA Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 389. MEA Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 390. Middle East Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 391. Middle East Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 392. Middle East Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 393. Middle East Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 394. Middle East Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 395. Middle East Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 396. Middle East Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 397. Africa Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 398. Africa Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 399. Africa Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 400. Africa Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 401. Africa Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 402. Africa Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 403. Africa Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 404. North America Male Hypogonadism, by Country USD Million (2025-2030)
  • Table 405. North America Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 406. North America Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 407. North America Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 408. North America Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 409. North America Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 410. North America Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 411. North America Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 412. United States Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 413. United States Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 414. United States Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 415. United States Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 416. United States Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 417. United States Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 418. United States Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 419. Canada Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 420. Canada Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 421. Canada Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 422. Canada Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 423. Canada Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 424. Canada Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 425. Canada Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 426. Mexico Male Hypogonadism, by Type USD Million (2025-2030)
  • Table 427. Mexico Male Hypogonadism, by Application USD Million (2025-2030)
  • Table 428. Mexico Male Hypogonadism, by Therapy USD Million (2025-2030)
  • Table 429. Mexico Male Hypogonadism, by Treatment USD Million (2025-2030)
  • Table 430. Mexico Male Hypogonadism, by Diagnosed USD Million (2025-2030)
  • Table 431. Mexico Male Hypogonadism, by Cause USD Million (2025-2030)
  • Table 432. Mexico Male Hypogonadism, by Drug Delivery USD Million (2025-2030)
  • Table 433. Research Programs/Design for This Report
  • Table 434. Key Data Information from Secondary Sources
  • Table 435. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Male Hypogonadism: by Type USD Million (2018-2023)
  • Figure 5. Global Male Hypogonadism: by Application USD Million (2018-2023)
  • Figure 6. Global Male Hypogonadism: by Therapy USD Million (2018-2023)
  • Figure 7. Global Male Hypogonadism: by Treatment USD Million (2018-2023)
  • Figure 8. Global Male Hypogonadism: by Cause USD Million (2018-2023)
  • Figure 9. Global Male Hypogonadism: by Drug Delivery USD Million (2018-2023)
  • Figure 10. South America Male Hypogonadism Share (%), by Country
  • Figure 11. Asia Pacific Male Hypogonadism Share (%), by Country
  • Figure 12. Europe Male Hypogonadism Share (%), by Country
  • Figure 13. MEA Male Hypogonadism Share (%), by Country
  • Figure 14. North America Male Hypogonadism Share (%), by Country
  • Figure 15. Global Male Hypogonadism share by Players 2023 (%)
  • Figure 16. Global Male Hypogonadism share by Players (Top 3) 2023(%)
  • Figure 17. Global Male Hypogonadism share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Astrazeneca Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Astrazeneca Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co. Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Laboratories Genevrier (France) Revenue, Net Income and Gross profit
  • Figure 24. Laboratories Genevrier (France) Revenue: by Geography 2023
  • Figure 25. Eli Lilly and Company Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company Ltd. (United States) Revenue: by Geography 2023
  • Figure 27. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 29. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 31. Pfizer Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer Inc.(United States) Revenue: by Geography 2023
  • Figure 33. Allergan Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Allergan Plc. (Ireland) Revenue: by Geography 2023
  • Figure 35. Ferring (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Ferring (Switzerland) Revenue: by Geography 2023
  • Figure 37. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Global Male Hypogonadism: by Type USD Million (2025-2030)
  • Figure 40. Global Male Hypogonadism: by Application USD Million (2025-2030)
  • Figure 41. Global Male Hypogonadism: by Therapy USD Million (2025-2030)
  • Figure 42. Global Male Hypogonadism: by Treatment USD Million (2025-2030)
  • Figure 43. Global Male Hypogonadism: by Cause USD Million (2025-2030)
  • Figure 44. Global Male Hypogonadism: by Drug Delivery USD Million (2025-2030)
  • Figure 45. South America Male Hypogonadism Share (%), by Country
  • Figure 46. Asia Pacific Male Hypogonadism Share (%), by Country
  • Figure 47. Europe Male Hypogonadism Share (%), by Country
  • Figure 48. MEA Male Hypogonadism Share (%), by Country
  • Figure 49. North America Male Hypogonadism Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Astrazeneca Plc. (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Laboratories Genevrier (France)
  • Eli Lilly and Company Ltd. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bayer AG (Germany)
  • Pfizer Inc.(United States)
  • Allergan Plc. (Ireland)
  • Ferring (Switzerland)
  • AbbVie Inc. (United States)
Additional players considered in the study are as follows:
IBSA Institut Biochimque (Slovakia) , Endo International Plc. (Ireland)
Select User Access Type

Key Highlights of Report


Apr 2024 248 Pages 89 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Male Hypogonadism Quantitative research analysis
Global Male Hypogonadism Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Astrazeneca Plc. (United Kingdom), Merck & Co. Inc. (United States), Laboratories Genevrier (France), Eli Lilly and Company Ltd. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Bayer AG (Germany), Pfizer Inc.(United States), Allergan Plc. (Ireland), Ferring (Switzerland) and AbbVie Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"High adoption of hormones therapy with increasing cases of hypogonadism" is seen as one of major influencing trends for Male Hypogonadism Market during projected period 2023-2030.
The Male Hypogonadism market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Male Hypogonadism Report?

Have a Query? Click Here

Other Related Reports

Insomnia Drugs Comprehensive Study by Type (Prescription-based Drugs, OTC Drugs, Herbal Drugs), Application (Hospitals, Clinics, Research Centres, Others), Distribution Channel (Retail Pharmacies, On...
$ 3450
Thrombin Comprehensive Study by Type (Bovine Thrombin, Human Thrombin, Recombinant Thrombin), Dosage Form (Powder Form, Solution Form), End User (Hospitals, Diagnostics Centers & Clinics, Ambulatory ...
$ 3450
Heavy Metal Poisoning Drugs Comprehensive Study by Type (ALN-TMP, Deferasirox, Deferoxamine Mesylate, Emeramide, Others), Application (Arsenic Toxicity, Chromium Toxicity, Copper Toxicity, Lead Toxic...
$ 3750
Pharmaceutical Robots Comprehensive Study by Type (Traditional Robots {Articulated, SCARA, Delta Parallel and Cartesian}, Collaborative Robots), Application (Picking and Packaging, Inspection of Drug...
$ 3450
Hypertension Drugs Comprehensive Study by Type (Systemic Hypertension Drugs, Pulmonary Hypertension Drugs), Application (Hospital Use, Clinic Use, Others), Distribution Channel (Retail Pharmacies, Ho...
$ 3750
High Blood Pressure Drugs Comprehensive Study by Type (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Vasodilators, Alpha Blockers, Re...
$ 3750